Long-term real costs of a strategy using rituximab as first-line treatment for patients with moderate-to-severe pemphigus: Evaluation from the French healthcare system
J Eur Acad Dermatol Venereol. 2024 Dec 12.
doi: 10.1111/jdv.20497.
Online ahead of print.